{"filing":{"accession_number":"0001129928-26-000047","cik":"0001129928","ticker":"ONCY","company_name":"ONCOLYTICS BIOTECH INC","form":"8-K","filing_date":"2026-07-24","report_date":"2026-07-20","primary_document":"oncy-20260720.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1129928/000112992826000047/oncy-20260720.htm"},"events":[{"id":20497,"run_id":18449,"accession_number":"0001129928-26-000047","anchor_item_number":"3.01","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"summary":"Oncolytics Biotech received formal notice from Nasdaq on July 20, 2026, that its common stock failed to meet the $1.00 minimum bid price requirement for 30 consecutive business days, triggering a 180-calendar-day compliance period ending January 19, 2027. The filing explicitly discloses the delisting risk and the conditions under which the company's stock would be subject to delisting if it fails to regain compliance. This is a textbook delisting-risk disclosure under Item 3.01.","company_name":"ONCOLYTICS BIOTECH INC","ticker":"ONCY","filing_date":"2026-07-24","form":"8-K","submitted_at":null,"items":[{"id":19870,"accession_number":"0001129928-26-000047","item_number":"3.01","item_title":"Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"reasoning":"Oncolytics Biotech received formal notice from Nasdaq on July 20, 2026, that its common stock failed to meet the $1.00 minimum bid price requirement for 30 consecutive business days, triggering a 180-calendar-day compliance period ending January 19, 2027. The filing explicitly discloses the delisting risk and the conditions under which the company's stock would be subject to delisting if it fails to regain compliance. This is a textbook delisting-risk disclosure under Item 3.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-24T20:41:36.646806+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":19870,"accession_number":"0001129928-26-000047","item_number":"3.01","item_title":"Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"reasoning":"Oncolytics Biotech received formal notice from Nasdaq on July 20, 2026, that its common stock failed to meet the $1.00 minimum bid price requirement for 30 consecutive business days, triggering a 180-calendar-day compliance period ending January 19, 2027. The filing explicitly discloses the delisting risk and the conditions under which the company's stock would be subject to delisting if it fails to regain compliance. This is a textbook delisting-risk disclosure under Item 3.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-24T20:41:36.646806+00:00","company_name":"ONCOLYTICS BIOTECH INC","ticker":"ONCY","filing_date":"2026-07-24"}]}